Aquafil H1 2026 slides: margins expand despite revenue dip

Aquafil reported 1H 2026 revenue of €269.5m (-4.2% YoY) but grew EBITDA 5.7% to €40.6m as margins expanded from 13.6% to 15.0%, alongside a 51.0% jump in net profit to €3.4m. Net debt fell to €196.9m (down €12.6m, -6.0% YoY) and leverage improved to 2.64x from 2.89x, supported by €36.0m operating cash flow. Management flagged ongoing demand uncertainty and higher raw material/transport costs in Q2 (expected to be absorbed via pass-through), targeting €8–10m annual cost savings in 2026–27 while keeping a stability-growth outlook.

Analysis

The equity story here is less about demand growth and more about whether Aquafil can convert a pricing-lag business into a cash-compounding story before input inflation re-accelerates. The operating leverage is real, but it is also fragile: a 3-month pass-through in most lines and a 6-month lag in textile yarn means reported margins can look better for a quarter or two even if end-demand remains flat. That creates a near-term window where consensus may overestimate the durability of the margin step-up.

The strategic implication is that recycled nylon is becoming a cost-competitive substitute, not just an ESG premium product. If management actually closes the cost gap with petrochemical nylon, the pressure falls on virgin nylon suppliers and on carpet/flooring customers that have been paying for sustainability branding; they either accept lower unit economics or accelerate recycled-content adoption. The second-order winner is any downstream brand that can market lower-carbon input without taking a material COGS hit.

The main risk is that the current improvement in debt metrics is partly a function of working capital timing and lower capex intensity, not yet a fully self-funding growth model. If caprolactam stays near recent highs or European BCF demand remains soft, the deleveraging narrative can stall quickly, and a 2.6x leverage profile is not enough to insulate a microcap from multiple compression. Watch Q3/Q4 pricing realization, not just EBITDA, as the falsifier.

Contrarian take: the market may be underappreciating how much of the thesis depends on execution rather than macro beta. This is not a clean 'green materials' momentum trade; it is a small, illiquid industrial with a long path to proving that cost savings can outrun input inflation. In a risk-on tape, the stock can rerate, but the more durable move requires evidence that free cash flow is repeatable after pass-through normalization.

Key Decisions for Investors

• Starter long ECNLF only on confirmation that Q3 pricing pass-through offsets caprolactam/transport inflation; use current weakness as entry, but keep size small given microcap liquidity and the need for proof of cash conversion.
• Do not chase the name on the basis of the current EBITDA beat alone; if Q3 gross margin does not hold or net debt fails to fall again, exit the thesis. Key falsifier: leverage not improving below ~2.5x EBITDA by year-end.
• Watchlist alert: if caprolactam remains above the recent ~€3,000/ton area into Q4 without corresponding price recovery, treat ECNLF as a margin-trap and fade any rally.
• Relative-value idea: favor downstream carpet/flooring beneficiaries with recycled-input optionality over upstream nylon suppliers if you want ESG-content exposure without single-name balance-sheet risk; ECNLF is the cleaner operating story, but the worse liquidity name.
• No high-conviction options trade here unless borrow/liquidity improves; the better risk/reward is a patient cash-equity position after the next quarter validates that the margin improvement is structural, not just lagged pricing.